Developing Countries

This page lists 255 references in the Main Healthy Skepticism Library relevant to Developing Countries.

Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.


HSL6963
Krentel A, Fischer P, Manoempil P, Supali T, Servais G, Ruckert P.
Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia
Trop Med Int Health 2006 Nov 1;11(11):1731-40

HSL6975
Tonby K.
[Forgotten diseases and new drugs].
Tidsskr Nor Laegeforen 2006 Oct 19;126(20):2694-6
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1443907

HSL6788
Lassen LC, Thomsen MK.
[Global health--the ethical responsibility of the pharmaceutical industry].
Ugeskr Laeger 2006 Sep 4;168(36):2994-5

HSL6702
Serdobova I, Kieny MP.
Assembling a global vaccine development pipeline for infectious diseases in the developing world.
Am J Public Health 2006 Sep 01;96(9):1554-9
http://www.ajph.org/cgi/content/full/96/9/1554

HSL6800
Akunyili D.
Dora Akunyili: battling against counterfeit drugs. Interview by Marilynn Larkin.
Lancet Infect Dis 2006 Sep 01;6(9):554-5
http://linkinghub.elsevier.com/retrieve/pii/S1473-3099(06)70575-8

HSL6887
Liyanage SS, Raina Macintyre C.
Do financial factors such as author page charges and industry funding impact on the nature of published research in infectious diseases?
Health Info Libr J 2006 Sep 01;23(3):214-22
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1471-1842.2006.00665.x

HSL6649
Heinig MJ.
The international code of marketing of breastmilk substitutes: the challenge is choice.
J Hum Lact 2006 Aug 01;22(3):265-6
http://jhl.sagepub.com/cgi/reprint/22/3/265

HSL6759
Singh R.
Clinical research in China and India: a paradigm shift in drug development.
Drug Discov Today 2006 Aug 01;11(15-16):675-6
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T64-4KDJSRH-1&_coverDate=08%2F31%2F2006&_alid=461531159&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5020&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=88c01c8110497ffd3807a6a69916127d

HSL6837
Kabra SK, Lodha R.
Irrational combination of montelukast and bambuterol for management of childhood asthma.
Indian Pediatr 2006 Aug 01;43(8):743-4
http://www.indianpediatrics.net/aug2006/743.pdf

HSL5991
Roehr B.
Roche’s tiered pricing enables poorer countries to stockpile drugs
BMJ 2006 Jul 8;333(7558):63
http://bmj.bmjjournals.com/cgi/content/short/333/7558/63?etoc

HSL5948
Zarocostas J.
Drug company chief urges faster introduction of new vaccines in poor nations.
BMJ 2006 Jul 1;333(7557):11
http://bmj.bmjjournals.com/cgi/content/short/333/7557/11-a?etoc

HSL6734
Ramiah I, Reich MR.
Building effective public-private partnerships: experiences and lessons from the African Comprehensive HIV/AIDS Partnerships (ACHAP).
Soc Sci Med 2006 Jul 01;63(2):397-408
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-4J91NKK-1&_coverDate=07%2F31%2F2006&_alid=461495471&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=b3f8ebbd7104c18eff8b823df7a465b0

HSL6806
Milstien JB, Kaddar M, Kieny MP.
The impact of globalization on vaccine development and availability.
Health Aff (Millwood) 2006 Jul-Aug 01;25(4):1061-9
http://content.healthaffairs.org/cgi/content/full/25/4/1061

HSL6885
Dubey AK, Palaian S, Shankar PR, Mishra P, Prabhu M, Bhandari RB, Chhetri AK.
Introduction to medication errors and the error prevention initiatives in a teaching hospital in Western Nepal.
Pak J Pharm Sci 2006 Jul 01;19(3):244-51

HSL5955
Mokhiber R, Weissman R.
A New Way For Drug Development?
corp-focus 2006 Jun 30
http://lists.essential.org/pipermail/corp-focus/2006/000244.html

HSL5733
Richards T.
The great medicines scandal.
BMJ 2006 Jun 10;332(7554):1345-6
http://bmj.bmjjournals.com/cgi/content/full/332/7554/1345

HSL5770
Couper MR, Pal SN, Rago L, Sawyer J.
WHO perspective on preventing avoidable harm from medicines.
BMJ 2006 Jun 10;332(7554):1393-4
http://bmj.bmjjournals.com/cgi/content/short/332/7554/1393-b?etoc

HSL5559
Zhang Y, Harvey KJ.
Rational antibiotic use in China: Lessons learnt through introducing surgeons to Australian guidelines.
Aust New Zealand Health Policy 2006 May 30;3(1):5
http://www.anzhealthpolicy.com/content/3/1/5

HSL5618
Chirac P, Torreele E.
Global framework on essential health R&D.
Lancet 2006 May 13;367(9522):1560-1
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)68672-8

HSL5622
Watson R.
EU companies can export generic versions of patented drugs to poor countries.
BMJ 2006 May 13;332(7550):1112
http://bmj.bmjjournals.com/cgi/content/full/332/7550/1112-a

HSL5664
Check E.
Are rich nations up for drug reform?
Nature 2006 May 11;441(7090):135
http://www.nature.com/doifinder/10.1038/441135a

HSL6210
Shiwani MH.
Quest of prescribing practice in Pakistan.
J Pak Med Assoc 2006 May 01;56(5):249-50

HSL6330
Noehrenberg E.
Report of the Commission on Intellectual Property Rights, Innovation and Public Health: an industry perspective.
Bull World Health Organ 2006 May 01;84(5):419-20
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862006000500027&lng=en&nrm=iso&tlng=en

HSL6331
Aoki R, Kubo K, Yamane H.
Patent policy and public health in developing countries: lessons from Japan.
Bull World Health Organ 2006 May 01;84(5):417-8
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862006000500026&lng=en&nrm=iso&tlng=en

HSL6758
Bignone IM.
[Issues regarding the legal regulation of drugs in Argentina].
Vertex 2006 May-Jun 01;17(67):220-3

HSL6012
Mansfield PR.
Universal Hepatitis-B Vaccination in India: A Questionable Strategy
BMJ 2006 Apr 7;302
http://bmj.bmjjournals.com/cgi/eletters/332/7545/804

HSL6011
Mansfield PR, Phadke A, Kale A.
Blanket hepatitis B vaccination is questionable in India
BMJ 2006 Apr 1;332(7547):976

HSL5502
Basu S, Andrews J, Smith-Rohrberg D.
Populations who test drugs should benefit from them.
Nature 2006 Mar 30;440(7084):605
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3094&uid=16572144&db=PubMed&url=http://dx.doi.org/10.1038/440605d

HSL6715
Nau JY.
[When Doctors Without Borders writes to Miles White, chairman of Abbott Laboratories].
Rev Med Suisse 2006 Mar 29;2(59):882

HSL5504
Drowning or thirsting: the extremes of availability of medical information.
PLoS Med 2006 Mar 01;3(3):e165
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030165

HSL6221
Dandona L.
Clinical trials in India: balancing economic opportunity with the public health context.
Natl Med J India 2006 Mar-Apr 01;19(2):57-9

HSL6851
Ridley DB, Grabowski HG, Moe JL.
Developing drugs for developing countries.
Health Aff (Millwood) 2006 Mar-Apr 01;25(2):313-24
http://content.healthaffairs.org/cgi/content/full/25/2/313

HSL6852
Drugs and vaccines around the world.
Health Aff (Millwood) 2006 Mar-Apr 01;25(2):312
http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?itool=Citation-def&PrId=3051&uid=16522572&db=PubMed&url=http://content.healthaffairs.org/cgi/pmidlookup?view=long&pmid=16522572

HSL5988
Tanner JA.
WTO TRIPS and its effect on the supply and development of medicines in China.
Hong Kong Med J 2006 Feb 01;12(1):84-6
http://www.hkmj.org.hk/hkmj/abstracts/v12n1/84.htm

HSL5261
Herrling P.
Experiments in social responsibility.
Nature 2006 Jan 19;439(7074):267-8
http://www.nature.com/doifinder/10.1038/439267a

HSL6231
Sethi M, Mishra D.
Display of feeding bottles in advertising renditions.
Indian J Pediatr 2006 Jan 01;73(1):104-5
http://www.ijppediatricsindia.org/article.asp?issn=0019-5456;year=2006;volume=73;issue=1;spage=104;epage=105;aulast=Sethi

HSL5311
Jayaraman KS.
Firms discovering reality of clinical research in India.
Nat Rev Drug Discov 2006 Jan;5(1):6

HSL5347
Wogart JP, Calcagnotto G.
Brazil's fight against AIDS and its implications for global health governance.
Healthc Q 2006;9(1):76-89

HSL6207
Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, Zafar H, Kumar R.
Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan.
J Pharm Pharm Sci 2006;9(1):50-9
http://www.ualberta.ca/~csps/JPPS9(1)/Rohra.D/promotion.htm

HSL4044
Zarocostas J.
WTO amendment on generic drugs draws mixed reaction.
BMJ 2005 Dec 17;331(7530):1421
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16356954&query_hl=2&itool=pubmed_docsum

HSL5292
Garcia J, Datol-Barrett E, Dizon M.
Industry experience in promoting weekly iron-folic acid supplementation in the Philippines.
Nutr Rev 2005 Dec;63(12)
http://www.ingentaconnect.com/content/ilsi/nure/2005/00000063/A00112s1/art00012?token=004c18a25f8359ad332b25757d5c4f6d4e227a677e442f20675d3676677053234a6c78737b65

HSL5353
Lichtenberg FR.
Pharmaceutical innovation and the burden of disease in developing and developed countries.
J Med Philos 2005 Dec;30(6):663-90
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16396790&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=0360-5310&volume=30&issue=6&spage=663

HSL6718
Kirk DD, Robert JS.
Assessing commercial feasibility: a practical and ethical prerequisite for human clinical testing.
Account Res 2005 Oct-Dec 01;12(4):281-97

HSL5234
Ballantyne A.
HIV international clinical research: exploitation and risk.
Bioethics 2005 Oct;19(5-6):476-91

HSL5745
Mamdani B, Mamdani M.
Colonialism of clinical trials: discerning the positive spin offs.
Indian J Med Ethics 2005 Oct-Dec;2(4):132-3

HSL6841
Nyigo VA, Malebo HM.
Drug discovery and developments in developing countries: bottlenecks and way forward.
Tanzan Health Res Bull 2005 Sep 01;7(3):154-8

HSL4202
Jayaraman KS.
Biotech boom.
Nat Biotechnol 2005 Sep 01;23(9):1183-4
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3094&uid=16151411&db=pubmed&url=http://dx.doi.org/10.1038/nbt0905-1183

HSL5574
Mastroianni Pde C, Galduroz JC, Carlini EA.
Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom.
Sao Paulo Med J 2005 Sep 1;123(5):209-14
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000500002&tlng=es&lng=en&nrm=iso

HSL4052
Havlir DV, Hammer SMPatents versus patients.
Antiretroviral therapy in India?
N Engl J Med 2005 Aug 25;353(8):749-51
http://content.nejm.org/cgi/content/extract/353/8/749

HSL6574
Giri BR, Shankar PR.
Learning how drug companies promote medicines in Nepal.
PLoS Med 2005 Aug 01;2(8):e256
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020256

HSL4192
Yidong G.
Pharma moves ahead cautiously in China.
Science 2005 Jul 29;309(5735):735
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051&uid=16051788&db=pubmed&url=http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=16051788

HSL4201
Padma TV.
India's drug tests.
Nature 2005 Jul 28;436(7050):485
http://www.nature.com/doifinder/10.1038/436485a

HSL5083
Hale VG, Woo K, Lipton HL.
Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.
Health Aff (Millwood) 2005 Jul-Aug;24(4):1057-63
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051&uid=16012146&db=PubMed&url=http://content.healthaffairs.org/cgi/pmidlookup?view=long&pmid=16012146

HSL4058
Bateman C.
Government 'encouraging snake-oil salesman' Rath.
S Afr Med J 2005 Jun 01;95(6):372,
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3401&uid=16100880&db=PubMed&url=http://blues.sabinet.co.za/WebZ/Authorize?sessionid=0:autho=pubmed:password=pubmed2004&/AdvancedQuery?&format=F&next=images/ejour/m_samj/m_samj_v95_n6_a4.pdf

HSL4236
Watson J.
Vitamin guru provokes wRath of scientists, activists.
Nat Med 2005 Jun 01;11(6):581
http://www.nature.com/doifinder/10.1038/nm0605-581a

HSL4057
Wilmshurst JM, van Toorn R, Newton CR.
Withdrawal of parenteral phenobarbitone--implications for resource-poorcountries.
S Afr Med J 2005 Jun 01;95(6):422-3
http://blues.sabinet.co.za/WebZ/Authorize?sessionid=0:autho=pubmed:password=pubmed2004&/AdvancedQuery?&format=F&next=images/ejour/m_samj/m_samj_v95_n6_a17.pdf

HSL4251
Longstaff C, Thelwell C, Whitton C.
The poor quality of streptokinase products in use in developing countries.
J Thromb Haemost 2005 May 01;3(5):1092-3
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3046&uid=15869616&db=pubmed&url=http://dx.doi.org/10.1111/j.1538-7836.2005.01271.x

HSL4260
Longstaff C, Thelwell C, Whitton C.
Regulatory frameworks in developing countries.
Nat Biotechnol 2005 Apr 01;23(4):413
http://www.nature.com/doifinder/10.1038/nbt0405-413a

HSL4267
Lawrence R.
New opportunities in Asia: a focus on India and China.
Drug Discov Today 2005 Jan 15;10(2):89-91
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T64-4FGWYRP-6&_coverDate=01%2F15%2F2005&_alid=362934848&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5020&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=4d53ce3a1764cb7e12a6d44c2c452e52

HSL5468
Rataboli PV, Garg A.
Confusing brand names: nightmare of medical profession.
J Postgrad Med 2005 Jan-Mar;51(1):13-6
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3153&uid=15793332&db=PubMed&url=http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2005;volume=51;issue=1;spage=13;epage=16;aulast=Rataboli

HSL5086
Andrews J.
U..S. Military sponsored vaccine trials and la resistance in Nepal.
Am J Bioeth 2005 Summer;5(3):W1-3 2005 Summer;5(3):W1-3
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16006352&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=1526-5161&volume=5&issue=3&spage=W1

HSL5395
Pecoul B.
New drugs for neglected diseases: from pipeline to patients.
PLoS Med 2004 Oct;1(1):e6

HSL5437
Gupta AS.
Intellectual capital as property.
Indian J Med Ethics 2004 Oct-Dec;1(4):115-6

HSL2082
Brieger WR, Osamor PE, Salami KK, Oladepo O, Otusanya SA.
Interactions between patent medicine vendors and customers in urban and rural Nigeria.
Health Policy Plan 2004 May;19(3):177-82
http://heapol.oxfordjournals.org/cgi/reprint/19/3/177

HSL4045
Sterckx S.
Patents and access to drugs in developing countries: an ethical analysis.
Developing World Bioeth 2004 May;4(1):58-75
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15086374&query_hl=2&itool=pubmed_docsum

HSL5208
Malavige GN.
Doctors, drug companies and medical ethics: a Sri Lankan perspective.
Indian J Med Ethics 2004 Jan-Mar;1(1):26

HSL5210
Dabade G.
Unhealthy drug donations.
Indian J Med Ethics 2004 Jan-Mar;1(1):18

HSL5211
Bal A.
Can the medical profession and the pharmaceutical industry work ethically for better health care?
Indian J Med Ethics 2004 Jan-Mar;1(1):17

HSL5212
Gulhati CM.
Needed: closer scrutiny of clinical trials.
Indian J Med Ethics 2004 Jan-Mar;1(1):4-5

HSL1924
Collins K.
Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health.
Perspect Biol Med 2004 Win;47(1):100-9
http://muse.jhu.edu/cgi-bin/access.cgi?uri=/journals/perspectives_in_biology_and_medicine/v047/47.1collins.html&session=85559565

HSL4241
Srivastava R, Chandra A, Kumar G.
Strategic imperatives for globalization of industries in developing countries: an Indian pharmaceutical industry example.
Health Mark Q 2004;22(1):57-69

HSL4269
Puska P, Lehtomaki P, Eckstein H, Juvonen H.
[Sources of medicine for developing countries].
Duodecim 2004;120(23):2833-40

HSL5438
Kabra SG.
Unsafe abortions and experimental excesses.
Issues Med Ethics 2003 Jul-Sep 01;11(3):79-80

HSL5439
Kietinun S, Gupte MD, Sengupta A.
A clinical trial in a developing country: many questions, few answers.
Issues Med Ethics 2003 Jul-Sep;11(3):89-90

HSL1391
Shah , S.
Globalization of clinical research by the pharmaceutical industry
Int J Health Serv 2003;33(1):29-36

HSL2225
Shah S.
Globalization of clinical research by the pharmaceutical industry.
Int J Health Serv 2003;33(1):29-36

HSL2236
Motchane JL.
Health for all or riches for some: WHO's responsible?
Int J Health Serv 2003;33(2):395-400

HSL5307
Carr DM.
Pfizer's epidemic: a need for international regulation of human experimentation in developing countries.
Case West Reserve J Int Law 2003 Win;35(1):15-53

HSL6145
Russell FM, Shann F, Curtis N, Mulholland K.
Evidence on the use of paracetamol in febrile children.
Bull World Health Organ 2003;81(5):367-72
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862003000500011&lng=en&nrm=iso&tlng=en

HSL2375
Miles MP, Munilla LS, Covin JG.
The Constant Gardener revisited: the effect of social blackmail on the marketing concept, innovation, and entrepreneurship.
J Bus Ethics 2002 Dec;41(3):287-95
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12755097

HSL2876
Dukes MN.
Accountability of the pharmaceutical industry.
Lancet 2002 Nov 23;360(9346):1682-4
http://linkinghub.elsevier.com/retrieve/pii/S0140673602115996

HSL2866
Henry D, Lexchin J.
The pharmaceutical industry as a medicines provider.
Lancet 2002 Nov 16;360(9345):1590-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12443614

HSL2882
Dal-Pizzol F.
Drug advertisements in less-developed countries.
Lancet 2002 Apr 20;359(9315):1439-40
http://linkinghub.elsevier.com/retrieve/pii/S0140673602083836

HSL2879
D'Mello B.
Transnational pharmaceutical corporations and neo-liberal business ethics in India.
J Bus Ethics 2002 Mar;36(1-2):165-85
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12625343

HSL6146
Shann F.
Research in developing countries.
N Engl J Med 2002 Feb 21;346(8):627-8

HSL5849
Attaran A, Gillespie-White L.
Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?
JAMA 2001 Oct 17;286(15):1886-92
http://jama.ama-assn.org/cgi/content/full/286/15/1886

HSL5314
Gupta AS.
Research on hire.
Issues Med Ethics 2001 Oct-Dec;9(4):111-3

HSL2741
Lal A.
Pharmaceutical drug promotion: how it is being practiced in India?
J Assoc Physicians India 2001 Feb;49:266-73

HSL5440
Jesani A.
Calls for advertising and market reforms in health care.
Issues Med Ethics 2001 Jan-Mar;9(1):19

HSL5441
Mamdani B, Mamdani M.
Ethics of professional advertising.
Issues Med Ethics 2001 Jan-Mar;9(1):18

HSL5442
Malpani A.
Doctors should be allowed to advertise.
Issues Med Ethics 2001 Jan-Mar;9(1):16-7

HSL5443
Pandya SK.
Advertising remains unethical even in the digital age.
Issues Med Ethics 2001 Jan-Mar;9(1):15

HSL2135
Okoro EO, Davies AE.
Sponsorship of educational programmes in Nigerian medical and pharmacy schools by pharmaceutical companies: possible risk implication for public health.
Ethics Med 2001 Spr;17(1):52-60

HSL5315
Bhatt AD.
Clinical trial publications.
Issues Med Ethics 2000 Oct-Dec;8(4):119-21

HSL2997
Sarmiento A.
Medicine and industry: The payer, the piper, and the tune
Annales CRMCC 2000 Apr;33(3):144-149

HSL5278
Phatak A.
The pharmaceutical industry and the medical profession.
Issues Med Ethics 1998 Oct-Dec;6(4):131-2

HSL694
Menkes DB.
Hazardous drugs in developing countries.
BMJ 1997 Dec 13;315(7122):1557-8
http://bmj.bmjjournals.com/cgi/content/full/315/7122/1557

HSL723
Gitanjali B, Shashindran CH, Tripathi KD, Sethuraman KR.
Are drug advertisements in Indian edition of BMJ unethical?
BMJ 1997 Aug 23;315(7106):459
http://www.bmj.com/cgi/content/full/315/7106/459

HSL733
Christo GG, Balasubramaniam R.
Commentary: advertising adversities.
BMJ 1997 Aug 23;315(7106):460
http://www.bmj.com/cgi/content/full/315/7106/460

HSL710
Lal A, Moharana AK, Srivastava S.
Comparative evaluation of drug advertisements in Indian, British and American medical journals.
J Indian Med Assoc 1997 Jan;95(1):19-20

HSL691
Ollila E, Hemminki E.
Does licensing of drugs in industrialized countries guarantee drug quality and safety for Third World countries?
International Journal of Health Services 1997;27:309-328
Nil

HSL778
Lal A, Moharana AK, Chandra P, Ray A.
Critical evaluation of references in drug advertisements: an Indian experience.
J Assoc Physicians India 1996 Nov;44(11):778-9

HSL798
Dikshit RK, Dikshit N.
What information is available on request from drug advertisers in India?
BMJ 1996 Oct 5;313(7061):855-6
http://www.bmj.com/cgi/content/full/313/7061/855

HSL777
Lal A, Sethi A.
Drug package inserts in India.
Ann Pharmacother 1996 Sep;30(9):1041

HSL749
Van DER, S , Whyte SR, Hardon A.
The anthropology of pharmaceuticals: a bibliographical approach
Annual Review of Anthropology 1996;25:155-178

HSL836
Lal A, Sethi A, Ray A.
Informing patients about drugs.
Natl Med J India 1995 Jan-Feb;8(1):36-8

HSL1709
Cárdenas EZ, Isenrich LL.
Prescribing habits of Peruvian physicians and factors influencing them
Bulletin of PAHO 1995;29:328-337

HSL6729
Mansfield PR.
MaLAM: encouraging trustworthy drug promotion
Essential Drugs Monitor 1994(17):6

HSL5703
Medawar C.
Drug information.
Lancet 1993 Dec 11;342(8885):1490-1

HSL6255
Re: the promotion of Septrin (co-trimoxazole)
1993 Oct

HSL5791
Sommers E.
Drug advertising
Canadian Medical Association Journal 1993;146:1230

HSL2141
Ranwella S.
Sri Lankan students campaign for rational medicine: the story of SIRHA.
Essent Drugs Monit 1993(16):10

HSL5168
Braithwaite , J .
Transnational regulation of the pharmaceutical industry
Annals of the American Academy of Political and Social Science 1993;525:12-30

HSL5192
Frankel D.
Drug labelling in developing countries
Lancet 1993;341:1469

HSL5549
Drug promotion: stealth, wealth, and safety
The Lancet 1993;341:1507-1508

HSL5132
Re: the promotion of aspirin
1992 Nov 1

HSL5131
Scanlan C .
Unsafe drugs find buyers abroad
MaLAM International Newsletter 1992 Oct 1:3-6

HSL4985
Africa survey shows pharma information valued
Health Horizons 1992 Oct(17):12-13

HSL4987
Whither WHO’s ethical criteria?
Health Horizons 1992 Oct(17):26

HSL4979
Darbourne A.
Pharmaceuticals in the Third World—progress or crisis?
Scrip Magazine 1992 Jul-Aug(6):6-8

HSL4970
Re: the promotion of chloramphenicol/streptomycin and Benadryl Expectorant and Humagel
1992 May

HSL4965
Quijano RF.
Prescribing habits and attitudes of medical practitioners in the Philippines
Drug Monitor 1992 Mar-Apr;7(2):15-27

HSL4850
Lexchin J.
Pharmaceutical promotion in the Third World
Journal of Drug Issues 1992;22:417-453

HSL4862
Montagne M.
Drug advertising and promotion: an introduction
Journal of Drug Issues 1992;22:195-203

HSL4774
Lexchin J.
Drug promotion: two views. Canada
INRUD News 1991 Dec;2(2):3

HSL4775
Suryawati S, Santoso B.
Drug promotion: two views. Indonesia
INRUD News 1991 Dec;2(2):3

HSL3131
Lee PR, Lurie P, Silverman MM, Lydecker M.
Drug promotion and labeling in developing countries: an update.
J Clin Epidemiol 1991;44

HSL4664
Herxheimer A, Lundborg CS, Westerholm B.
Advertisements for medicines in medical journals: a collaborative international study
1991

HSL4708
Smith NC, Quelch JA.
Pharmaceutical marketing practices in the Third World
Journal of Business Research 1991;23:113-126

HSL4714
Üstel I, Herxheimer A.
Progress in medicines control
Lancet 1991;337:905-906

HSL4631
Saade C, Huff-rousselle M.
Pakistan: should ORS be marketed like other drugs?
Dialogue on Diarrhoea 1990 Sep(42):6

HSL4527
Use of drugs in childhood: a preliminary study in Malaysia
Education and Research Association for Consumer (ERA Consumer) 1990 Aug 12-16

HSL4607
MaLAM letter follow up—FCE admit data sheet was obsolete
MaLAM Newsletter 1990 Mar:2

HSL4500
Ahmad SR, Bhutta ZA.
A survey of pediatric prescribing and dispensing in Karachi
Journal of the Pakistan Medical Association 1990;40:126-130

HSL4521
Chetley A.
A healthy business? World health and the pharmaceutical industry
Zed Books 1990
http://www.amazon.com/Healthy-Business-Health-Pharmaceutical-Industry/dp/0862327350/ref=sr_1_1/102-1249992-1219339?ie=UTF8&s=books&qid=1174978013&sr=1-1

HSL4525
Double standard labelling of pharmaceuticals sold in Thailand
Drug Study Group 1990:3

HSL4538
Herxheimer A.
Medicines in francophone Africa
Lancet 1990;335:1449-1450

HSL4606
Zaini J.
Pushing children’s vitamins
HAI News 1990(51):1-2, 11

HSL4492
MaLAM letter follow up—Merck Sharp & Dohme. Are MSD’s distributors uncontrollable?
MaLAM Newsletter 1989 Nov

HSL4493
Re: the promotion of uridine triphosphate
1989 Nov

HSL4487
MaLAM letter follow up—Wellcome: a welcome withdrawal
MaLAM Newsletter 1989 Oct

HSL4488
Re: the promotion of Franol combination for asthma
1989 Oct

HSL4483
Children’s vitamin preparations: kidding the kids and their parents
1989 Aug;4(8):109-110

HSL4484
Re: the promotion of serrapeptase
1989 Aug

HSL4479
MaLAM letter follow-up—Merck Sharp & Dohme. Denial of responsibility
MaLAM Newsletter 1989 Jun

HSL4480
Re: the promotion of tetracycline syrups for children
1989 Jun

HSL4482
Re: the promotion of buflomedil
1989 Jun

HSL4476
Re: the promotion of nicergoline
1989 May

HSL4468
This month’s MaLAM letter—Glaxo. Multiple claims, little improvement
MaLAM Newsletter 1989 Apr

HSL4469
Logarta JD.
Generics revisited: an overdose of expectations
Drug Monitor 1989 Apr;4(4):49-54

HSL4464
Re: the promotion of ketoconazole
1989 Feb

HSL4127
Birley JL.
Drug advertisements in developing countries.
Lancet 1989 Jan 28;1(8631):220

HSL4461
Highlights of a survey of Southeast Asian physicians
Drug Monitor 1989 Jan;4(1):8

HSL4462
MaLAM letter follow up—Last gasps for a respiratory stimulant
MaLAM Newsletter 1989 Jan:1

HSL4117
Misuse of antidiarrhoeal medicines
Lancet 1989;2:995

HSL4455
Sriwatanakul K.
Trials of dipyrone in Thailand
Lancet 1989;1:788

HSL4489
Antidiarrhoeals again under attack
Scrip 1989(1457):29

HSL4010
Kiatboonsri P, Richter J.
Unethical trials of dipyrone in Thailand.
Lancet 1988 Dec 24-31;2(8626-8627):1491

HSL4108
Re: the promotion of erythromycin with bromhexine
1988 Nov

HSL4110
Danguilan MJ.
Drug commercials scored
Drug Monitor 1988 Nov;3(11):129-130

HSL4027
Nahata MC.
Drug package information in India.
Drug Intell Clin Pharm 1988 Sep;22(9):719

HSL4101
Re: the promotion of Rogin E
1988 Sep

HSL4076
Vo-kyung S, Ok KIM.
Investigation of the violations of pharmaceutical regulations in advertisements of children’s medicines
1988 Aug 18-20

HSL4069
Smith EL.
Drug promotion in the Third World.
Lancet 1988 Jul 23;2(8604):224

HSL4097
Re: the promotion of cefuroxime, cyanocobalamin, cephalexin, ranitidine and guaiphenesin
1988 Jun

HSL4088
Healthcare communications and pharmaceutical promotion
Health Horizons 1988 May(4):16-17

HSL4090
Re: the promotion of high dose oestradiol and progesterone and high dose oestradiol and testosterone
1988 May

HSL4082
Re: the promotion of penicillin/streptomycin combination
1988 Feb

HSL3985
International medical advertising
Lancet 1988;1:350

HSL3996
Ferguson A.
Commercial pharmaceutical medicine and medicalization: a case study from El Salvador
1988

HSL3999
Harvey K.
The impact of the WHO ethical criteria for medicinal drug promotion: a study by Health Action International (HAI)
1988:4
www.haiweb.org

HSL4028
Osiobe SA.
Physicians’ and pharmacists’ drug information sources in Nigeria
Drug Information Journal 1988;22:553-563

HSL4033
Pleil AM, Pathak DS.
Commercial drug compendium information: a First World/Third World comparison.
Int J Health Serv 1988;18(4):587-602

HSL4070
Sterky G, Tomson G, Sachs L, Henningsson B, Bergman U.
Medicines and society: a challenge in health development
1988

HSL4072
Tan M.
Dying for drugs: pill power and politics in the Philippines
1988

HSL4104
Hardon A.
Towards rational drug-use in urban primary health care
Drug Monitor 1988;3(10):111-119

HSL3977
MaLAM letter follow up—Bayer
MaLAM Newsletter 1987 Oct

HSL3978
Re: the promotion of lincomycin and clindamycin
1987 Oct

HSL3979
Re: the promotion of trimethoprim/sulphamethoxazole/guaiphenesin/ammonium chloride
1987 Oct

HSL3980
Advertisement of Rx drugs to health professionals
1987 Oct:17

HSL3974
The IFPMA code: how it works and how it’s working
International Federation of Pharmaceutical Manufacturers Associations 1987 Sep
www.ifpma.rog/hhhs/welcome.htm

HSL3975
Re: the promotion of flunarizine
1987 Sep

HSL3970
DOH proposes regulating of drug ads
Drug Monitor 1987 Aug;2(8):3-5

HSL3973
Organon and anabolic steroids
WEMOS pharma group 1987 Aug

HSL3964
MaLAM letter follow up—Janssen
MaLAM Newsletter 1987 Jun:1-2

HSL3965
MaLAM letter follow up—Parke-Davis
MaLAM Newsletter 1987 Jun:1

HSL3966
MaLAM letter follow up—Sandoz
MaLAM Newsletter 1987 Jun

HSL3936
Double standards—some improvements
HAI News 1987 Feb(33):1-2, 12

HSL3937
MLAM letter follow up—Pfizer
1987 Feb:2

HSL3957
Re: the promotion of co-dergocrine
1987 Feb

HSL3958
Re: the promotion of loperamide
1987 Feb

HSL3935
Hoechst a cause of illness? The pharmabusiness in the Third World
1987 Jan

HSL3883
Greenhalgh T.
Drug prescription and self-medication in India: an exploratory survey.
Soc Sci Med 1987;25(3):307-18

HSL3930
Wolffers I.
Drug information and sale practices in some pharmacies of Colombo, Sri Lanka.
Soc Sci Med 1987;25(3):319-21

HSL3852
MLAM letter follow up—Pfizer
MLAM Newsletter 1986 Nov

HSL3853
Re: the promotion of arsenic/strychnine
1986 Nov

HSL3849
MLAM letter follow up—Parke Davis/Warner Lambert
MLAM Newsletter 1986 Oct

HSL3850
Re: the promotion of oral streptomycin/chloramphenicol combination
1986 Oct

HSL3851
Greenhalgh T.
Beneath cosmetic reforms
HAI News 1986 Oct

HSL3783
Greenhalgh T.
Drug marketing in the Third World: beneath the cosmetic reforms.
Lancet 1986 Jun 7;1(8493):1318-20

HSL3837
Re: the promotion of Rheopyrine
1986 Apr

HSL3835
Re: the promotion of Primobolan and Fortabol
1986 Mar

HSL3834
Re: the promotion of ibuprofen syrup
1986 Feb

HSL3758
Need for a rational drugs policy
Lancet 1986;1:262

HSL3764
Bhattacharjee PK.
Marketing drugs in the Third World
Lancet 1986;2:576

HSL3784
Greenhalgh T.
Marketing drugs in the Third World
Lancet 1986;2:222

HSL3799
Lee A.
Marketing drugs in the Third World
Lancet 1986;2:222

HSL3804
Mamdani M, Walker G.
Essential drugs in the developing world
Health Policy and Planning 1986;1:187-201

HSL3821
Silverman M, Lee PR, Lydecker M.
Drug promotion: the Third World revisited.
Int J Health Serv 1986;16(4):659-67

HSL3753
Re: the promotion of Entero-Sediv
1985 Dec 01

HSL3750
Re: the promotion of anabolic steroids for children
1985 Nov 01

HSL3729
Osiobe SA.
Sources of information for biomedical decision-making.
Methods Inf Med 1985 Oct;24(4):225-9

HSL3748
Re: the promotion of vitamins A & E
1985 Sep 01

HSL3747
Re: the promotion of tetracycline
1985 Aug 01

HSL3742
Re: the promotion of pizotifen
1985 Jun 01

HSL3746
Re: the promotion of ampicillin (Binotal) in Indonesia
1985 Jun 01

HSL3743
Mansfield PR.
Protecting the innocent from harm: the Medical Lobby for Appropriate Marketing (MLAM)
New Doctor 1985 Jun(36):22-24

HSL3722
Loshak D.
Anti-inflammatory drugs under fire.
Lancet 1985 Feb 16;1(8425):410

HSL3710
Collier J.
Ethics of drug marketing
Lancet 1985;1:166-167

HSL3730
Osiobe SA.
Use of information resources by health professionals: a review of the literature.
Soc Sci Med 1985;21(9):965-73

HSL3733
Van DER.
Marketing myths: selling drugs in the Third World
Medicine in Society 1985;2(2):41-45

HSL3692
Re: the promotion of Binotal
1984 Dec 01

HSL3664
Yudkin JS.
Use and misuse of drugs in the Third World.
Dan Med Bull 1984 Nov;31

HSL3661
Wolffers I.
Telling doctors in a developing country about phenylbutazone.
Lancet 1984 Jul 7;2(8393):44

HSL3681
Re: the promotion of ethylestrenol
1984 Jul 01

HSL3619
Bansinath M, Sequeira RP, Shukla VK, Mathur VS.
Brand versus generic prescribing: a perspective of the Indian cardiologists' viewpoint.
Int J Clin Pharmacol Ther Toxicol 1984 Jun;22(6):279-83

HSL3677
Re: the promotion of Lomotil
1984 May 01

HSL3673
Re: the promotion of dipyrone
1984 Apr 01

HSL3617
Organon censured for marketing of anabolic steroids in developing countries
Lancet 1984;1:155

HSL3656
Timmers R.
Legibility of advertisements
Lancet 1984;2:1396

HSL3658
Turner J.
World health assembly
Lancet 1984;1:1172-1173

HSL3608
Re: the promotion of products containing amidopyrine
1983 Nov

HSL3572
Barker C.
The Mozambique pharmaceutical policy.
Lancet 1983 Oct 1;2(8353):780-2

HSL3569
Pharmaceutical policies for the Third World--whose responsibility.
Lancet 1983 Jul 16;2(8342):144

HSL3591
Osifo NG.
Overpromotion of drugs in international product package inserts.
Trop Doct 1983 Jan;13(1):5-8

HSL3593
Quraeshi ZA, Luqmani M, Malhotra N.
Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
J Health Care Mark 1983 Fal;3(4):27-37

HSL3546
Melrose D.
Bitter pills: medicines and the Third World poor
1982

HSL3531
Drugs and the Third World
Lancet 1982;2:1351

HSL3545
Medawar C.
Marketing and use of pharmaceuticals—bad information means bad medicine
1982

HSL3548
Muller M.
The health of nations: a north-south investigation
: Faber and Faber; 1982

HSL3553
Silverman M, Lee PR, Lydecker M.
The drugging of the Third World.
Int J Health Serv 1982;12(4):585-96

HSL3554
Silverman M, Lee PR, Lydecker M.
Prescriptions for death: the drugging of the Third World
Berkeley: University of California Press; 1982

HSL3529
Richter R.
Pesticides and pills: for export only Part two: pharmaceuticals
1981 Oct 24

HSL3513
Jayasuriya DC.
Regulating the drug trade in the Third World
World Health Forum 1981;2:423-426

HSL3522
Silverman M, Lydecker M.
The promotion of prescription drugs and other puzzles
1981:78-92

HSL3463
Epstein P, Yudkin JS.
Agranulocytosis in Mozambique due to amidopyrine, a drug withdrawn in the west.
Lancet 1980 Aug 2;2(8188):254-5

HSL3473
Johnston TS.
Provision of medicines in Ecuador.
Lancet 1980 May 17;1(8177):1073-4

HSL3460
Ethics and drug ads—a slip up in Bangladesh
1980;208:268-269

HSL3487
Yudkin JS.
The economics of pharmaceutical supply in Tanzania.
Int J Health Serv 1980;10(3):455-77

HSL3397
Lall S, Bibile S.
The political economy of controlling transnationals: the pharmaceutical industry in Sri Lanka, 1972-1976.
Int J Health Serv 1978;8(2):299-328

HSL3406
Yudkin JS.
Provision of medicines in a developing country
Lancet 1978;1:810-812

HSL3380
Muller M.
Selling health - or buying favour?
New Scientist 1977 Feb 3;73:266-268

HSL3356
Heller T.
Poor health, rich profits: multinational drug companies and the Third World
Spokesman Books 1977

HSL3372
Silverman M.
The epidemiology of drug promotion
International Journal of Health Services 1977;7:157-166

HSL3250
Schreier HA, Berger L.
Letter: On medical imperialism.
Lancet 1974 Jun 8;1(7867):1161